Neonatal lung ultrasonography score after surfactant in preterm infants: A prospective observational study

Pediatr Pulmonol. 2020 Jan;55(1):116-121. doi: 10.1002/ppul.24566. Epub 2019 Nov 11.

Abstract

Objective: To assess changes in neonatal lung ultrasonography score (nLUS) after surfactant administration in preterm infants with respiratory distress syndrome (RDS).

Working hypothesis: The reduction of nLUS score before (nLUSpre), 2 hours (nLUS2h), and 12 hours (nLUS12h) after surfactant administration to identify patients who will not need a second treatment.

Study design and setting: Prospective observational study in the tertiary neonatal intensive care unit.

Patients selection: Forty-six preterm neonates with RDS of 32 weeks median gestational age (IQR 30-33) and mean birth weight of 1650 ± 715 g.

Methodology: Lung ultrasonography was performed before, 2 hours, and 12 hours after surfactant administration in preterm infants with RDS needing surfactant treatment. Resulting nLUS was analyzed.

Results: The Wilcoxon signed-rank test demonstrated an nLUS lowering after 2 hours (P < .001) and 12 hours (P < .001) from surfactant administration. Sixteen newborns required surfactant retreatment with median gestational age of 32 weeks (IQR 29-33) and mean birth weight of 1519 ± 506 g.The receiver operating characteristic analysis for the nLUS2h yielded an area under the curve of 0.80 (95% confidence interval, 0.76-0.85; P < .001). A nLUS2h ≥7 showed a sensitivity of 94% and a specificity of 60% for needing a second treatment with surfactant.

Conclusions: In preterm infants with RDS requiring surfactant treatment, nLUS evaluated 2 hours after surfactant administration can be used to identify patients who will not need a second treatment.

Keywords: LUS patterns; LUS score; lung ultrasonography; respiratory distress syndrome; surfactant therapy.

Publication types

  • Observational Study

MeSH terms

  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Prospective Studies
  • Pulmonary Surfactants / therapeutic use*
  • ROC Curve
  • Respiratory Distress Syndrome, Newborn / diagnostic imaging*
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Ultrasonography

Substances

  • Pulmonary Surfactants